董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Rocklage | 男 | Director | 61 | 8.07万美元 | 未持股 | 2016-04-15 |
| Daotian Fu | 男 | Director | 53 | 7.07万美元 | 未持股 | 2016-04-15 |
| Amit Munshi | 男 | Director, President, Chief Executive Officer | 48 | 364.60万美元 | 未持股 | 2016-04-15 |
| Julie H. McHugh | 女 | Director | 51 | 8.11万美元 | 未持股 | 2016-04-15 |
| J. Kevin Buchi | 男 | Director | 60 | 8.57万美元 | 未持股 | 2016-04-15 |
| Geoffrey Duyk | 男 | Director | 57 | 7.80万美元 | 未持股 | 2016-04-15 |
| Mark H. N. Corrigan | 男 | Director, Chairman of the Board | 58 | 9.28万美元 | 未持股 | 2016-04-15 |
| William Hunter | 男 | Director | 53 | 7.59万美元 | 未持股 | 2016-04-15 |
| J. Kevin Buchi | 男 | Director | 60 | 未披露 | 未持股 | 2016-04-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas Shea | 男 | Senior Vice President, Chief Financial Officer and Treasurer | 56 | 126.72万美元 | 未持股 | 2016-04-15 |
| Amit Munshi | 男 | Director, President, Chief Executive Officer | 48 | 364.60万美元 | 未持股 | 2016-04-15 |
| Michael Wyand | 男 | Senior Vice President, Chief Technical Officer | 60 | 127.95万美元 | 未持股 | 2016-04-15 |
| Robert Ticktin | 男 | Senior Vice President, General Counsel and Secretary | 54 | 未披露 | 未持股 | 2016-04-15 |
| Vincent Aurentz | 男 | Senior Vice President, Chief Business Officer | 48 | 未披露 | 未持股 | 2016-04-15 |
董事简历
中英对照 | 中文 | 英文- Scott Rocklage
-
Scott Rocklage，2013年起，担任本公司董事。他于2003年加入风投公司5AM Ventures，担任风险合伙人；于2004年成为管理合伙人。加入5AM Ventures之前，1994-2003，他担任Cubist Pharmaceuticals Inc的首席执行官、董事长，这是上市的制药公司；1986-1989，担任诊断成像公司Nycomed Salutar, Inc的总裁、首席执行官。他还在私营制药公司Nycomed and Catalytica, Inc担任过多个研发职务。他目前是制药公司Novira, Inc.、生物可再生化学私营公司Rennovia, Inc、私营技术公司Kinestral Technologies的董事长。他还任职于下列董事会：Achaogen, Inc.，生物制药上市企业； Pulmatrix, Inc.， 生物技术私营企业；Epirus Biopharmaceuticals, Inc.， 生物制药上市企业。他在University of California, Berkeley获得化学学士学位，在Massachusetts Institute of Technology获得化学博士学位。
Scott Rocklage, Ph.D.,has served as a member of our Board since 2013. Dr. Rocklage joined 5AM Ventures, a venture capital firm, in 2003 as a Venture Partner and became a Managing Partner in 2004. Prior to joining 5AM Ventures, Dr. Rocklage served as Chief Executive Officer and Chairman of the Board of Cubist Pharmaceuticals Inc., a publicly-traded pharmaceutical company, from 1994 to 2003 and as President and Chief Executive Officer of Nycomed Salutar, Inc., a diagnostic imaging company, from 1986 to 1989. Dr. Rocklage has also served in various research and development positions at Nycomed and Catalytica, Inc., a private pharmaceutical company. Dr. Rocklage currently serves as the chairman of the board of directors of Rennovia, Inc., a private bio-renewable chemical company, Kinestral Technologies, a private technology company, Aprea Therapeutics, a private biopharmaceutical company, and Expansion Therapeutics, a private biopharmaceutical company. Dr. Rocklage previously served on the board of directors of Achaogen, Inc., Epirus Biopharmaceuticals, Inc., Relypsa, Inc., and VBI Vaccines, Inc., all public biopharmaceutical companies, and Pulmatrix, Inc., a public biotechnology company. Dr. Rocklage holds a B.S. in chemistry from the University of California, Berkeley and a Ph.D. in chemistry from the Massachusetts Institute of Technology. - Scott Rocklage，2013年起，担任本公司董事。他于2003年加入风投公司5AM Ventures，担任风险合伙人；于2004年成为管理合伙人。加入5AM Ventures之前，1994-2003，他担任Cubist Pharmaceuticals Inc的首席执行官、董事长，这是上市的制药公司；1986-1989，担任诊断成像公司Nycomed Salutar, Inc的总裁、首席执行官。他还在私营制药公司Nycomed and Catalytica, Inc担任过多个研发职务。他目前是制药公司Novira, Inc.、生物可再生化学私营公司Rennovia, Inc、私营技术公司Kinestral Technologies的董事长。他还任职于下列董事会：Achaogen, Inc.，生物制药上市企业； Pulmatrix, Inc.， 生物技术私营企业；Epirus Biopharmaceuticals, Inc.， 生物制药上市企业。他在University of California, Berkeley获得化学学士学位，在Massachusetts Institute of Technology获得化学博士学位。
- Scott Rocklage, Ph.D.,has served as a member of our Board since 2013. Dr. Rocklage joined 5AM Ventures, a venture capital firm, in 2003 as a Venture Partner and became a Managing Partner in 2004. Prior to joining 5AM Ventures, Dr. Rocklage served as Chief Executive Officer and Chairman of the Board of Cubist Pharmaceuticals Inc., a publicly-traded pharmaceutical company, from 1994 to 2003 and as President and Chief Executive Officer of Nycomed Salutar, Inc., a diagnostic imaging company, from 1986 to 1989. Dr. Rocklage has also served in various research and development positions at Nycomed and Catalytica, Inc., a private pharmaceutical company. Dr. Rocklage currently serves as the chairman of the board of directors of Rennovia, Inc., a private bio-renewable chemical company, Kinestral Technologies, a private technology company, Aprea Therapeutics, a private biopharmaceutical company, and Expansion Therapeutics, a private biopharmaceutical company. Dr. Rocklage previously served on the board of directors of Achaogen, Inc., Epirus Biopharmaceuticals, Inc., Relypsa, Inc., and VBI Vaccines, Inc., all public biopharmaceutical companies, and Pulmatrix, Inc., a public biotechnology company. Dr. Rocklage holds a B.S. in chemistry from the University of California, Berkeley and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
- Daotian Fu
-
Daotian Fu，现任Livzon Pharmaceutical Group Inc. 的副总裁、董事；还是Livzon MabPharm Inc.的总经理，这是Livzon Pharmaceutical Group Inc.参与资助的早期阶段生物开发公司。加入Livzon之前，他在 Genzyme担任了10年多的副总裁，负责所有生物开发的质量控制和分析发展。他还曾担任一些技术及管理职务，其中包括Charles River Lab的总监、Neose Pharmaceuticals的经理。
Daotian Fu has served as a member of our board of directors since the Merger closed in July 2014. Dr. Fu is Vice President and director of Livzon Pharmaceutical Group Inc. He is also General Manager of Livzon MabPharm Inc., an early stage biologics development company partially funded by Livzon Pharmaceutical Group Inc. Prior to joining Livzon, Dr. Fu was Vice President at Genzyme for over ten years where he was responsible for the quality control and analytical development of all biologics in development. He has also held several technical and management positions, including Director at Charles River Laboratories and Manager of Neose Pharmaceuticals. - Daotian Fu，现任Livzon Pharmaceutical Group Inc. 的副总裁、董事；还是Livzon MabPharm Inc.的总经理，这是Livzon Pharmaceutical Group Inc.参与资助的早期阶段生物开发公司。加入Livzon之前，他在 Genzyme担任了10年多的副总裁，负责所有生物开发的质量控制和分析发展。他还曾担任一些技术及管理职务，其中包括Charles River Lab的总监、Neose Pharmaceuticals的经理。
- Daotian Fu has served as a member of our board of directors since the Merger closed in July 2014. Dr. Fu is Vice President and director of Livzon Pharmaceutical Group Inc. He is also General Manager of Livzon MabPharm Inc., an early stage biologics development company partially funded by Livzon Pharmaceutical Group Inc. Prior to joining Livzon, Dr. Fu was Vice President at Genzyme for over ten years where he was responsible for the quality control and analytical development of all biologics in development. He has also held several technical and management positions, including Director at Charles River Laboratories and Manager of Neose Pharmaceuticals.
- Amit Munshi
-
Amit Munshi，自2014年7月15日合并完成之时起，担任本公司的总裁、首席执行官、董事；此前，从2012年5月起，担任Private Epirus的总裁、首席执行官、董事。2011年，他担任Percivia LLC的首席执行官；2005年8月至2010年12月，还是上市公司Kythera Biopharmaceuticals, Inc.的共同创始人、首席业务官。此前，他在Amgen Inc.担任过多个领导职务，其中包括肾脏病欧洲地区总经理。他在美国及国际地区拥有超过24年的制药和生物技术经验，涉及综合管理、产品开发、授权、业务开发。他现为多个私营公司的董事： Oxeia Biopharmaceuticals, Inc.、Adrista, Inc. 、Cytrellis Biosystems, Inc.；2005-2010，担任Nephrian, Inc.的董事；2012-2014，担任私营公司Cynvenio Biosystems, Inc.的董事。
Amit Munshi has served as President, Chief Executive Officer and a director of the Company since the Merger closed in July 2014 and prior to that time served as President and Chief Executive Officer and a director of Private Epirus beginning in May 2012. Mr. Munshi served as Chief Executive Officer of Percivia LLC in 2011 and also was a co-founder, and the chief business officer, at Kythera Biopharmaceuticals, Inc. acquired by Allegran Plc, a publicly traded company, from August 2005 until December 2010. Previously, he held leadership positions at Amgen Inc., including General Manager, Nephrology Europe. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc., of which he was a co-founder and executive officer, Adrista, Inc. and Cytrellis Biosystems, Inc., all of which are privately held companies, and previously served on the boards of Nephrian, Inc., a privately held company, from 2005 until 2010 and Cynvenio Biosystems, Inc., a privately held company, from 2012 until 2014. Mr. Munshi serves on the compensation committee of Oxeia Biopharmaceuticals. - Amit Munshi，自2014年7月15日合并完成之时起，担任本公司的总裁、首席执行官、董事；此前，从2012年5月起，担任Private Epirus的总裁、首席执行官、董事。2011年，他担任Percivia LLC的首席执行官；2005年8月至2010年12月，还是上市公司Kythera Biopharmaceuticals, Inc.的共同创始人、首席业务官。此前，他在Amgen Inc.担任过多个领导职务，其中包括肾脏病欧洲地区总经理。他在美国及国际地区拥有超过24年的制药和生物技术经验，涉及综合管理、产品开发、授权、业务开发。他现为多个私营公司的董事： Oxeia Biopharmaceuticals, Inc.、Adrista, Inc. 、Cytrellis Biosystems, Inc.；2005-2010，担任Nephrian, Inc.的董事；2012-2014，担任私营公司Cynvenio Biosystems, Inc.的董事。
- Amit Munshi has served as President, Chief Executive Officer and a director of the Company since the Merger closed in July 2014 and prior to that time served as President and Chief Executive Officer and a director of Private Epirus beginning in May 2012. Mr. Munshi served as Chief Executive Officer of Percivia LLC in 2011 and also was a co-founder, and the chief business officer, at Kythera Biopharmaceuticals, Inc. acquired by Allegran Plc, a publicly traded company, from August 2005 until December 2010. Previously, he held leadership positions at Amgen Inc., including General Manager, Nephrology Europe. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc., of which he was a co-founder and executive officer, Adrista, Inc. and Cytrellis Biosystems, Inc., all of which are privately held companies, and previously served on the boards of Nephrian, Inc., a privately held company, from 2005 until 2010 and Cynvenio Biosystems, Inc., a privately held company, from 2012 until 2014. Mr. Munshi serves on the compensation committee of Oxeia Biopharmaceuticals.
- Julie H. McHugh
-
Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University. - Julie H. McHugh，她曾担任Lantheus Holdings， Inc.的成员。自2015年6月起担任董事会成员。她曾担任Endo Health Solutions， Inc.的首席运营官（2010年3月至2013年5月退休），负责专业制药和仿制药业务。在此之前，她是Nora Therapeutics， Inc.（一家风险资本支持的生物技术初创公司，专注于开发治疗不孕症的新疗法）的首席执行官。此前，她曾担任Johnson & Johnson全球病毒学业务部门的公司集团主席，在此之前，她曾担任强生子公司Centocor， Inc.的总裁。在此职位上，她负责监督几种产品的开发和发布，包括Remicade infliximab， Prezista （darunavir）和intelligence （etravirine）。加入Centocor之前，她在Astra-Merck Inc.领导胃肠药物Prilosec（奥美拉唑）的营销传播。她目前担任Ironwood Pharmaceuticals， Inc.的董事会主席，以及Lantheus Holdings， Inc.、New Xellia Group A/S和Trevena Pharmaceuticals， Inc.的董事会成员。她曾担任the Biotechnology Industry Organization （BIO）、the New England Healthcare Institute （NEHI）、the Pennsylvania Biotechnology Association、EPIRUS Biopharmaceuticals, Inc.和ViroPharma Inc.的董事会成员。她在St. Joseph大学获得工商管理硕士学位，在Pennsylvania State大学获得学士学位。
- Julie H. McHugh,most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses.Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc.Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis.Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc.Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute.Ms. McHugh received her M.B.A. degree from St. Joseph's University and her B.S. degree from Pennsylvania State University.
- J. Kevin Buchi
-
J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX and Ampio Pharmaceuticals (NYSE:AMPE). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. - J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
- J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX and Ampio Pharmaceuticals (NYSE:AMPE). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.
- Geoffrey Duyk
-
Geoffrey Duyk 从2006年5月到2011年5月担任董事会成员。Duyk博士是技术投资公司Circularis Partners的合伙人。2004年至2017年，Duyk博士担任TPG Alternative & Renewable Technologies TPG ART的合伙人兼董事总经理，TPG ART是一家专注于技术的投资公司及其附属公司“TPG”。从1996年到2003年，他在Exelixis, Inc.(一家专注于药物研发的生物制药公司)的董事会任职，并担任研发总裁。在Exelixis之前，从1993年到1996年，Duyk博士是基因组学的副总裁和Millennium Pharmaceuticals的创始科学人员之一。在此之前，Duyk博士是哈佛医学院遗传学系的助理教授和霍华德休斯医学研究所的助理研究员。Duyk博士目前担任Anuvia Plant nutrition的董事会成员;Concentric Ag Corporation临时首席执行官(2019年以来);ReGen Holdings Limited以及非营利的凯斯西储大学董事会成员。他也是莫菲特癌症中心(the Moffitt Cancer Center)的研究所董事会成员，他在那里主持研究和发展委员会。他是OncoBay Clinical的董事会主席，OncoBay Clinical是一家私人合同研究机构(Moffitt Cancer Center的子公司)。Duyk博士是劳伦斯伯克利国家实验室(DOE)的科学顾问委员会成员和Innovatus Capital Partners的顾问委员会成员。此前，2005年8月至2017年6月，Duyk博士曾任职于多个咨询委员会、非营利、私人和上市公司董事会，包括Aerie Pharmaceuticals。他持有Wesleyan University的生物学学士学位、Case Western Reserve University的生物化学博士学位和医学博士学位。
Geoffrey Duyk previously served on the Board from May 2006 to May 2011. Dr. Duyk is a partner of Circularis Partners, a technology focused investment firm. Previously, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies TPG ART, a technology focused investment firm together with its affiliates, "TPG", from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Anuvia Plant Nutrients; Concentric Ag Corporation interim CEO since 2019; and ReGen Holdings Limited as well as on the nonprofit Case Western Reserve University Board of Trustees. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. He is the Chairman of the board of directors of OncoBay Clinical, a private contract research organization (subsidiary of Moffitt Cancer Center). Dr. Duyk serves as a member of Scientific Advisory Boards for Lawrence Berkeley National Laboratory (DOE) and a member of the Advisory Board of Innovatus Capital Partners. Previously, Dr. Duyk has served on a number of advisory boards, nonprofit, private, and public company boards, including Aerie Pharmaceuticals from August 2005 to June 2017. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and a Ph.D. in Biochemistry and M.D. from Case Western Reserve University. - Geoffrey Duyk 从2006年5月到2011年5月担任董事会成员。Duyk博士是技术投资公司Circularis Partners的合伙人。2004年至2017年，Duyk博士担任TPG Alternative & Renewable Technologies TPG ART的合伙人兼董事总经理，TPG ART是一家专注于技术的投资公司及其附属公司“TPG”。从1996年到2003年，他在Exelixis, Inc.(一家专注于药物研发的生物制药公司)的董事会任职，并担任研发总裁。在Exelixis之前，从1993年到1996年，Duyk博士是基因组学的副总裁和Millennium Pharmaceuticals的创始科学人员之一。在此之前，Duyk博士是哈佛医学院遗传学系的助理教授和霍华德休斯医学研究所的助理研究员。Duyk博士目前担任Anuvia Plant nutrition的董事会成员;Concentric Ag Corporation临时首席执行官(2019年以来);ReGen Holdings Limited以及非营利的凯斯西储大学董事会成员。他也是莫菲特癌症中心(the Moffitt Cancer Center)的研究所董事会成员，他在那里主持研究和发展委员会。他是OncoBay Clinical的董事会主席，OncoBay Clinical是一家私人合同研究机构(Moffitt Cancer Center的子公司)。Duyk博士是劳伦斯伯克利国家实验室(DOE)的科学顾问委员会成员和Innovatus Capital Partners的顾问委员会成员。此前，2005年8月至2017年6月，Duyk博士曾任职于多个咨询委员会、非营利、私人和上市公司董事会，包括Aerie Pharmaceuticals。他持有Wesleyan University的生物学学士学位、Case Western Reserve University的生物化学博士学位和医学博士学位。
- Geoffrey Duyk previously served on the Board from May 2006 to May 2011. Dr. Duyk is a partner of Circularis Partners, a technology focused investment firm. Previously, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies TPG ART, a technology focused investment firm together with its affiliates, "TPG", from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Anuvia Plant Nutrients; Concentric Ag Corporation interim CEO since 2019; and ReGen Holdings Limited as well as on the nonprofit Case Western Reserve University Board of Trustees. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. He is the Chairman of the board of directors of OncoBay Clinical, a private contract research organization (subsidiary of Moffitt Cancer Center). Dr. Duyk serves as a member of Scientific Advisory Boards for Lawrence Berkeley National Laboratory (DOE) and a member of the Advisory Board of Innovatus Capital Partners. Previously, Dr. Duyk has served on a number of advisory boards, nonprofit, private, and public company boards, including Aerie Pharmaceuticals from August 2005 to June 2017. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and a Ph.D. in Biochemistry and M.D. from Case Western Reserve University.
- Mark H. N. Corrigan
-
Mark H. N. Corrigan， 硕士学位。a Class II类董事，自2009年12月起担任 Zalicus董事。自2010年1月起担任 Zalicus总裁和首席执行官。2003年4月到2009年12月担任Sepracor Inc.（一家公开上市制造公司）研发部执行副总裁。加入Sepracor Inc.之前，他在Pharmacia & Upjohn（一家公开上市制造公司，2002年被Pfizer, Inc.收购）工作10年，最近的职位是担任 Global Clinical Research and Experimental Medicine集团副总裁。加入制药行业之前，他在the University of North Carolina Medical School进行5年的学术研究，主要研究心理神经内分泌学。他还担任 Cubist Pharmaceuticals, Inc.（一家公开上市生物制药公司）董事。他持有佛吉尼亚大学（the University of Virginia）文学学士学位以及硕士学位，之后不久还在 Cornell and Maine Medical Center受到了精神病学的特殊训练。
Mark H. N. Corrigan,has served as a director since September 2019. Since June 2021, Dr. Corrigan has served as a member of the board of directors of Nabriva Therapeutics plc, a publicly traded commercial-stage biopharmaceutical company, and previously served on its board of directors from June 2017 to May 2020. Dr. Corrigan also currently serves as chairman of the board of directors of Elios Therapeutics, LLC, a privately-held development-stage immuno-oncology company. Dr. Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. from March 2019 to May 2020. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co-founder) from 2016 to March 2019, and continues to serve on its board of directors. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia. - Mark H. N. Corrigan， 硕士学位。a Class II类董事，自2009年12月起担任 Zalicus董事。自2010年1月起担任 Zalicus总裁和首席执行官。2003年4月到2009年12月担任Sepracor Inc.（一家公开上市制造公司）研发部执行副总裁。加入Sepracor Inc.之前，他在Pharmacia & Upjohn（一家公开上市制造公司，2002年被Pfizer, Inc.收购）工作10年，最近的职位是担任 Global Clinical Research and Experimental Medicine集团副总裁。加入制药行业之前，他在the University of North Carolina Medical School进行5年的学术研究，主要研究心理神经内分泌学。他还担任 Cubist Pharmaceuticals, Inc.（一家公开上市生物制药公司）董事。他持有佛吉尼亚大学（the University of Virginia）文学学士学位以及硕士学位，之后不久还在 Cornell and Maine Medical Center受到了精神病学的特殊训练。
- Mark H. N. Corrigan,has served as a director since September 2019. Since June 2021, Dr. Corrigan has served as a member of the board of directors of Nabriva Therapeutics plc, a publicly traded commercial-stage biopharmaceutical company, and previously served on its board of directors from June 2017 to May 2020. Dr. Corrigan also currently serves as chairman of the board of directors of Elios Therapeutics, LLC, a privately-held development-stage immuno-oncology company. Dr. Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. from March 2019 to May 2020. Prior to joining Correvio, Dr. Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a co-founder) from 2016 to March 2019, and continues to serve on its board of directors. Dr. Corrigan served as President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr. Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000 to 2003, Dr. Corrigan served as Group Vice President, Clinical Research & Experimental Medicine at Pharmacia Corporation. Prior to this, Dr. Corrigan held various roles at The Upjohn Company, The University of North Carolina, and the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr. Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received a Bachelor of Arts in Psychology from the University of Virginia.
- William Hunter
-
William Hunter，Merger 2014年7月完成起担任我们董事会成员；此前，2009年12月起担任Pre-Merger Zalicus 董事。2012年7月起，在上市药物研发公司Cardiome Pharma Corp.担任总裁和首席执行官。2007年6月起，在Cardiome 董事会任职，2014年8月起，在上市公司International Healthcare Investments Limited董事会任职。他目前在Cardiome的提名和企业治理委员会任职。他1992年11月创立了上市医药和医疗设备公司Angiotech Pharmaceuticals, Inc.；担任董事、总裁和首席执行官到2011年10月。2011年1月，Angiotech自愿根据Canada Companies’ Creditors Arrangement Act the “CCAA”提交申请，进行由不列颠哥伦比亚省最高法院监督的重组，以及自愿根据美国破产法15章提交请愿，以在CCAA推动的重组下获得美国承认和执行。The Angiotech 重组2011年5月完成。Hunter 博士持有McGill 大学的理学士学位，以及British Columbia大学的硕士和医学博士学位。
William Hunter has served as a member of our board of directors since the Merger closed in July 2014 and prior to that time served as a director of Pre-Merger Zalicus beginning in December 2009. Dr. Hunter has been the President and Chief Executive Officer of Cardiome Pharma Corp., a publicly traded drug development and research company, since July 2012. Dr. Hunter has served on the board of directors of Cardiome since June 2007 and has served on the board of directors of International Healthcare Investments Limited, a publicly traded company, since August 2014. Dr. Hunter serves on the nominating and corporate governance committee of Cardiome. Dr. Hunter founded Angiotech Pharmaceuticals, Inc., a publicly traded pharmaceutical and medical device company in November 1992 and served as a director and its President and Chief Executive Officer until October 2011. In January 2011 Angiotech voluntarily filed under the Canada Companies’ Creditors Arrangement Act the “CCAA” to pursue a restructuring supervised by the Supreme Court of British Columbia, and also voluntarily filed a petition under Chapter 15 of the United States Bankruptcy Code to obtain recognition and enforcement in the United States of the restructuring being pursued under the CCAA proceedings. The Angiotech restructuring was completed in May 2011. Dr. Hunter holds a B.Sc. from McGill University and an M.Sc. and M.D. from the University of British Columbia. - William Hunter，Merger 2014年7月完成起担任我们董事会成员；此前，2009年12月起担任Pre-Merger Zalicus 董事。2012年7月起，在上市药物研发公司Cardiome Pharma Corp.担任总裁和首席执行官。2007年6月起，在Cardiome 董事会任职，2014年8月起，在上市公司International Healthcare Investments Limited董事会任职。他目前在Cardiome的提名和企业治理委员会任职。他1992年11月创立了上市医药和医疗设备公司Angiotech Pharmaceuticals, Inc.；担任董事、总裁和首席执行官到2011年10月。2011年1月，Angiotech自愿根据Canada Companies’ Creditors Arrangement Act the “CCAA”提交申请，进行由不列颠哥伦比亚省最高法院监督的重组，以及自愿根据美国破产法15章提交请愿，以在CCAA推动的重组下获得美国承认和执行。The Angiotech 重组2011年5月完成。Hunter 博士持有McGill 大学的理学士学位，以及British Columbia大学的硕士和医学博士学位。
- William Hunter has served as a member of our board of directors since the Merger closed in July 2014 and prior to that time served as a director of Pre-Merger Zalicus beginning in December 2009. Dr. Hunter has been the President and Chief Executive Officer of Cardiome Pharma Corp., a publicly traded drug development and research company, since July 2012. Dr. Hunter has served on the board of directors of Cardiome since June 2007 and has served on the board of directors of International Healthcare Investments Limited, a publicly traded company, since August 2014. Dr. Hunter serves on the nominating and corporate governance committee of Cardiome. Dr. Hunter founded Angiotech Pharmaceuticals, Inc., a publicly traded pharmaceutical and medical device company in November 1992 and served as a director and its President and Chief Executive Officer until October 2011. In January 2011 Angiotech voluntarily filed under the Canada Companies’ Creditors Arrangement Act the “CCAA” to pursue a restructuring supervised by the Supreme Court of British Columbia, and also voluntarily filed a petition under Chapter 15 of the United States Bankruptcy Code to obtain recognition and enforcement in the United States of the restructuring being pursued under the CCAA proceedings. The Angiotech restructuring was completed in May 2011. Dr. Hunter holds a B.Sc. from McGill University and an M.Sc. and M.D. from the University of British Columbia.
- J. Kevin Buchi
-
J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX, Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), and Ziopharm Oncology, Inc. (Nasdaq: ZIOP). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. - J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
- J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010 Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. NYSE: AMRX, Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), and Ziopharm Oncology, Inc. (Nasdaq: ZIOP). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.
高管简历
中英对照 | 中文 | 英文- Thomas Shea
Thomas Shea，2013年6月起担任高级副总裁、财务总监和司库。2011年-2013年6月，他在Euthymics Bioscience, Inc., Neurovance, Inc.和 EBI Life Sciences, Inc.担任财务总监，这3家附属公司开发神经和止痛的候选药物。此前，2005-2011年，在自身免疫公司 Tolerx, Inc.担任财务总监6年；在Cubist Pharmaceuticals, Inc. （被Merck & Co., Inc.收购）10年。在Cubist，他是该公司从私有转变为上市公司的领导团队中不可或缺的一员。目前还在私有公司Compliance Management Group董事会任职。
Thomas Shea has served as our Senior Vice President, Chief Financial Officer and Treasurer since June 2013. He was formerly the Chief Financial Officer of Euthymics Bioscience, Inc., Neurovance, Inc. and EBI Life Sciences, Inc., three affiliated companies developing neurological and pain drug candidates, from 2011 to June 2013. Previously, Mr. Shea was the Chief Financial Officer of Tolerx, Inc., an autoimmune company, for six years, from 2005 to 2011 and Cubist Pharmaceuticals, Inc. acquired by Merck & Co., Inc. for 10 years. At Cubist, Mr. Shea was an integral part of the leadership team transitioning the company from a private to a public company. Mr. Shea currently serves on the board of directors of Compliance Management Group, a private company.- Thomas Shea，2013年6月起担任高级副总裁、财务总监和司库。2011年-2013年6月，他在Euthymics Bioscience, Inc., Neurovance, Inc.和 EBI Life Sciences, Inc.担任财务总监，这3家附属公司开发神经和止痛的候选药物。此前，2005-2011年，在自身免疫公司 Tolerx, Inc.担任财务总监6年；在Cubist Pharmaceuticals, Inc. （被Merck & Co., Inc.收购）10年。在Cubist，他是该公司从私有转变为上市公司的领导团队中不可或缺的一员。目前还在私有公司Compliance Management Group董事会任职。
- Thomas Shea has served as our Senior Vice President, Chief Financial Officer and Treasurer since June 2013. He was formerly the Chief Financial Officer of Euthymics Bioscience, Inc., Neurovance, Inc. and EBI Life Sciences, Inc., three affiliated companies developing neurological and pain drug candidates, from 2011 to June 2013. Previously, Mr. Shea was the Chief Financial Officer of Tolerx, Inc., an autoimmune company, for six years, from 2005 to 2011 and Cubist Pharmaceuticals, Inc. acquired by Merck & Co., Inc. for 10 years. At Cubist, Mr. Shea was an integral part of the leadership team transitioning the company from a private to a public company. Mr. Shea currently serves on the board of directors of Compliance Management Group, a private company.
- Amit Munshi
Amit Munshi，自2014年7月15日合并完成之时起，担任本公司的总裁、首席执行官、董事；此前，从2012年5月起，担任Private Epirus的总裁、首席执行官、董事。2011年，他担任Percivia LLC的首席执行官；2005年8月至2010年12月，还是上市公司Kythera Biopharmaceuticals, Inc.的共同创始人、首席业务官。此前，他在Amgen Inc.担任过多个领导职务，其中包括肾脏病欧洲地区总经理。他在美国及国际地区拥有超过24年的制药和生物技术经验，涉及综合管理、产品开发、授权、业务开发。他现为多个私营公司的董事： Oxeia Biopharmaceuticals, Inc.、Adrista, Inc. 、Cytrellis Biosystems, Inc.；2005-2010，担任Nephrian, Inc.的董事；2012-2014，担任私营公司Cynvenio Biosystems, Inc.的董事。
Amit Munshi has served as President, Chief Executive Officer and a director of the Company since the Merger closed in July 2014 and prior to that time served as President and Chief Executive Officer and a director of Private Epirus beginning in May 2012. Mr. Munshi served as Chief Executive Officer of Percivia LLC in 2011 and also was a co-founder, and the chief business officer, at Kythera Biopharmaceuticals, Inc. acquired by Allegran Plc, a publicly traded company, from August 2005 until December 2010. Previously, he held leadership positions at Amgen Inc., including General Manager, Nephrology Europe. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc., of which he was a co-founder and executive officer, Adrista, Inc. and Cytrellis Biosystems, Inc., all of which are privately held companies, and previously served on the boards of Nephrian, Inc., a privately held company, from 2005 until 2010 and Cynvenio Biosystems, Inc., a privately held company, from 2012 until 2014. Mr. Munshi serves on the compensation committee of Oxeia Biopharmaceuticals.- Amit Munshi，自2014年7月15日合并完成之时起，担任本公司的总裁、首席执行官、董事；此前，从2012年5月起，担任Private Epirus的总裁、首席执行官、董事。2011年，他担任Percivia LLC的首席执行官；2005年8月至2010年12月，还是上市公司Kythera Biopharmaceuticals, Inc.的共同创始人、首席业务官。此前，他在Amgen Inc.担任过多个领导职务，其中包括肾脏病欧洲地区总经理。他在美国及国际地区拥有超过24年的制药和生物技术经验，涉及综合管理、产品开发、授权、业务开发。他现为多个私营公司的董事： Oxeia Biopharmaceuticals, Inc.、Adrista, Inc. 、Cytrellis Biosystems, Inc.；2005-2010，担任Nephrian, Inc.的董事；2012-2014，担任私营公司Cynvenio Biosystems, Inc.的董事。
- Amit Munshi has served as President, Chief Executive Officer and a director of the Company since the Merger closed in July 2014 and prior to that time served as President and Chief Executive Officer and a director of Private Epirus beginning in May 2012. Mr. Munshi served as Chief Executive Officer of Percivia LLC in 2011 and also was a co-founder, and the chief business officer, at Kythera Biopharmaceuticals, Inc. acquired by Allegran Plc, a publicly traded company, from August 2005 until December 2010. Previously, he held leadership positions at Amgen Inc., including General Manager, Nephrology Europe. Mr. Munshi serves on the boards of Oxeia Biopharmaceuticals, Inc., of which he was a co-founder and executive officer, Adrista, Inc. and Cytrellis Biosystems, Inc., all of which are privately held companies, and previously served on the boards of Nephrian, Inc., a privately held company, from 2005 until 2010 and Cynvenio Biosystems, Inc., a privately held company, from 2012 until 2014. Mr. Munshi serves on the compensation committee of Oxeia Biopharmaceuticals.
- Michael Wyand
Michael Wyand，2015年4月起，担任Epirus的高级副总裁、首席技术官；此前，从2012年6月起，担任临床、监管与制造高级副总裁。他曾担任的全球业务高级副总裁，从事新兴市场生物仿制分子药品的相关工作。此前，他曾在BioAssets Development Corporation, Inc. 担任开发高级副总裁，该公司来被出售给Cephalon Inc.；也曾是Therion Biologics Corporation的研发高级副总裁；任职于后者期间，他曾负责设计和建立了一个符合cGMP标准的生产设施，并推动适用于前列腺癌、胰腺癌的两种疫苗进入后期开发阶段。职业生涯之初，他曾担任Mason Laboratories的总裁、首席科学官，以及Genzyme Transgenics Corp.的临床前开发副总裁。
Michael Wyand has served as our Senior Vice President and Chief Technical Officer since April 2015 and previously served as our Senior Vice President of Clinical, Regulatory and Manufacturing from June 2012 through April 2015. Dr. Wyand is a former Senior Vice President of Global Operations of Percivia LLC where he worked from August 2011 to April 2012 on a portfolio of biosimilar molecules for emerging markets. Prior to that, Dr. Wyand was Senior Vice President of Development at BioAssets Development Corporation, Inc. sold to Cephalon Inc. from December 2007 to October 2010 and was a Senior Vice President of Research and Development at Therion Biologics Corporation from June 2001 to November 2006. At Therion, Dr. Wyand was responsible for designing and building a cGMP compliant manufacturing facility and taking two cancer vaccines for prostate and pancreatic cancer through later stage development. At the start of his career Dr. Wyand was President and Chief Scientific Officer of Mason Laboratories and served as Vice President of Preclinical Development at Genzyme Transgenics Corp. Prior to his 25 years of biopharmaceutical experience, Dr. Wyand trained in comparative pathology at Harvard Medical School, received his DVM from Purdue University and graduated as a University Scholar, Phi Beta Kappa, from the University of Connecticut.- Michael Wyand，2015年4月起，担任Epirus的高级副总裁、首席技术官；此前，从2012年6月起，担任临床、监管与制造高级副总裁。他曾担任的全球业务高级副总裁，从事新兴市场生物仿制分子药品的相关工作。此前，他曾在BioAssets Development Corporation, Inc. 担任开发高级副总裁，该公司来被出售给Cephalon Inc.；也曾是Therion Biologics Corporation的研发高级副总裁；任职于后者期间，他曾负责设计和建立了一个符合cGMP标准的生产设施，并推动适用于前列腺癌、胰腺癌的两种疫苗进入后期开发阶段。职业生涯之初，他曾担任Mason Laboratories的总裁、首席科学官，以及Genzyme Transgenics Corp.的临床前开发副总裁。
- Michael Wyand has served as our Senior Vice President and Chief Technical Officer since April 2015 and previously served as our Senior Vice President of Clinical, Regulatory and Manufacturing from June 2012 through April 2015. Dr. Wyand is a former Senior Vice President of Global Operations of Percivia LLC where he worked from August 2011 to April 2012 on a portfolio of biosimilar molecules for emerging markets. Prior to that, Dr. Wyand was Senior Vice President of Development at BioAssets Development Corporation, Inc. sold to Cephalon Inc. from December 2007 to October 2010 and was a Senior Vice President of Research and Development at Therion Biologics Corporation from June 2001 to November 2006. At Therion, Dr. Wyand was responsible for designing and building a cGMP compliant manufacturing facility and taking two cancer vaccines for prostate and pancreatic cancer through later stage development. At the start of his career Dr. Wyand was President and Chief Scientific Officer of Mason Laboratories and served as Vice President of Preclinical Development at Genzyme Transgenics Corp. Prior to his 25 years of biopharmaceutical experience, Dr. Wyand trained in comparative pathology at Harvard Medical School, received his DVM from Purdue University and graduated as a University Scholar, Phi Beta Kappa, from the University of Connecticut.
- Robert Ticktin
Robert Ticktin，2014年4月起，担任Epirus的高级副总裁、法律总顾问、秘书。此前，他从2004年起，担任Amgen Inc.的副法律总顾问，在法律部门担任过各种职务，涉及并购、授权、联盟管理、国际业务，以及最后阶段全球生产与采购业务的法律支持。职业生涯之初，他任职于纽约的全球性的法律公司Simpson Thacher & Bartlett LLP、Latham & Watkins LLP。他在The Ohio State University获得经济学士学位，在Fordham University School of Law获得法律博士学位。
Robert Ticktin has served as our Senior Vice President, General Counsel and Secretary since April 2014. Prior to that, since 2004 Mr. Ticktin was Associate General Counsel at Amgen Inc., where he held various positions in the legal department, including leading legal support for mergers & acquisitions, licensing, alliance management, international operations and, most recently, global production and procurement activities. Mr. Ticktin commenced his legal career in New York City at global law firms, Simpson Thacher & Bartlett LLP and Latham & Watkins LLP. Mr. Ticktin received a B.A. in Economics from The Ohio State University and a J.D. from Fordham University School of Law.- Robert Ticktin，2014年4月起，担任Epirus的高级副总裁、法律总顾问、秘书。此前，他从2004年起，担任Amgen Inc.的副法律总顾问，在法律部门担任过各种职务，涉及并购、授权、联盟管理、国际业务，以及最后阶段全球生产与采购业务的法律支持。职业生涯之初，他任职于纽约的全球性的法律公司Simpson Thacher & Bartlett LLP、Latham & Watkins LLP。他在The Ohio State University获得经济学士学位，在Fordham University School of Law获得法律博士学位。
- Robert Ticktin has served as our Senior Vice President, General Counsel and Secretary since April 2014. Prior to that, since 2004 Mr. Ticktin was Associate General Counsel at Amgen Inc., where he held various positions in the legal department, including leading legal support for mergers & acquisitions, licensing, alliance management, international operations and, most recently, global production and procurement activities. Mr. Ticktin commenced his legal career in New York City at global law firms, Simpson Thacher & Bartlett LLP and Latham & Watkins LLP. Mr. Ticktin received a B.A. in Economics from The Ohio State University and a J.D. from Fordham University School of Law.
- Vincent Aurentz
Vincent Aurentz，自2016年8月起担任Arena Pharmaceuticals, Inc.的执行副总裁兼首席业务官。此前，他曾担任Epirus biopharmacpharmaceuticals, Inc.的首席商务官(2015年11月至2016年7月)。加入Epirus之前，他曾担任HemoShear Therapeutics, LLC的总裁(从2013年7月到2015年11月)，负责科学研究和业务发展工作，包括与辉瑞公司(Pfizer Inc.)、礼来公司(Eli Lilly)、詹森研发公司(Janssen R&D)和儿童国家健康系统(Children’s National Health System)等全球组织的合作。从2015年11月起担任Zalicus Inc.高级副总裁、首席商务官。2013年7月-2015年11月，担任HemoShear Therapeutics总裁，监管科学和业务发展事务，包括与全球机构的合作如Pfizer, Eli Lilly, Janssen R&D和Children’s National Health System。此前，2012年7月-2013年12月，担任Merck KGaA Merck Serono的执行副总裁和执行管理委员会成员，领导研发项目、投资组合战略以及领导所有的交易活动和风投。2010年10月-2012年4月，在Quintiles担任执行副总裁，是一家风险资本和顾问公司的联合创始人和总经理；在Andersen Consulting （现为 Accenture）开始他的职业生涯。他获得Villanova University的数学学士学位。
Vincent Aurentz has served as our Senior Vice President and Chief Business Officer since November 2015. He was formerly the President of HemoShear Therapeutics, from July 2013 to November 2015 where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children's National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA Merck Serono, from July 2012 to December 2013 where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. He is a former Executive Vice President at Quintiles, where he served from October 2010 to April 2012 Co-founder and Managing Director of a venture capital and advisory business and started his career at Andersen Consulting (now Accenture).- Vincent Aurentz，自2016年8月起担任Arena Pharmaceuticals, Inc.的执行副总裁兼首席业务官。此前，他曾担任Epirus biopharmacpharmaceuticals, Inc.的首席商务官(2015年11月至2016年7月)。加入Epirus之前，他曾担任HemoShear Therapeutics, LLC的总裁(从2013年7月到2015年11月)，负责科学研究和业务发展工作，包括与辉瑞公司(Pfizer Inc.)、礼来公司(Eli Lilly)、詹森研发公司(Janssen R&D)和儿童国家健康系统(Children’s National Health System)等全球组织的合作。从2015年11月起担任Zalicus Inc.高级副总裁、首席商务官。2013年7月-2015年11月，担任HemoShear Therapeutics总裁，监管科学和业务发展事务，包括与全球机构的合作如Pfizer, Eli Lilly, Janssen R&D和Children’s National Health System。此前，2012年7月-2013年12月，担任Merck KGaA Merck Serono的执行副总裁和执行管理委员会成员，领导研发项目、投资组合战略以及领导所有的交易活动和风投。2010年10月-2012年4月，在Quintiles担任执行副总裁，是一家风险资本和顾问公司的联合创始人和总经理；在Andersen Consulting （现为 Accenture）开始他的职业生涯。他获得Villanova University的数学学士学位。
- Vincent Aurentz has served as our Senior Vice President and Chief Business Officer since November 2015. He was formerly the President of HemoShear Therapeutics, from July 2013 to November 2015 where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children's National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA Merck Serono, from July 2012 to December 2013 where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. He is a former Executive Vice President at Quintiles, where he served from October 2010 to April 2012 Co-founder and Managing Director of a venture capital and advisory business and started his career at Andersen Consulting (now Accenture).